参考文献

［1］MARCUM J A. The discovery of heparin: the contributions of William Henry Howell and Jay McLean ［J］. News Physiol Sci，1992，7:237-242.

［2］BARROWCLIFFE T W，GUTTERIDGE J M，DORMANDY T L. The effect of fatty-acid autoxidation products on blood coagulation［J］. Thromb Diath Haemorrh，1975，33（2）: 271-277.

［3］HOWELL W H. The purification of heparin and its chemical and physiologieal reactions ［J］. Bull John Hopkins Hosp，1928，42:199-206.

［4］CHARLES A F，SCOTT D A. Studies on heparin: I. the preparation of heparin ［J］. J Biol Chem，1933，102（2）: 425-429.

［5］JORPES E，BERGSTROM S. Der aminozucker des heparins［J］.Hoppe Seylers Z Physiol Chem，1936，244: 253-259.

［6］CIFONELLI J A，DORFMAN A. The uronic acid of heparin［J］.Biochem Biophys Res Commun，1962，7: 41-45.

［7］凌沛学，何兆雄，姬胜利.肝素［M］.北京：中国轻工出版社， 2016.

［8］JOHNSON E A，KIRKWOOD T B，STIRLING Y，et al. Four heparin preparations: anti-Ⅹa potentiating effect of heparin after subcutaneous injection［J］. Thromb Haemost，1976，35（3）:586-591.

［9］BARRITT D W，JORDAN S C. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial［J］. Lancet，1960，1（7138）: 1309-1312.

［10］KAKKAR V V. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial［J］. Lancet，1975，2（7924）: 45-51.

［11］KAKKAR V V，DJAZAERI B，FOK J，et al. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis［J］. Br Med J （Clin Res Ed），1982，284（6313）: 375-379.

［12］MEHTA S R，YUSUF S，GRANGER C B，et al. Design and rationale of the Michelangelo Organization to Assess Strategies in Acute Ischemic Syndromes （OASIS）-5 trial program evaluating fondaparinux，a synthetic factor Ⅹa inhibitor，in patients with non-ST-segment elevation acute coronary syndromes［J］. Am Heart J，2005，150（6）: 1107. uWOlUgOM5u7VdgR7se9ljiXB4U27MqG8mmEy855njgIn7ixywhH+Vqjfm3ZbQkh8